India, July 29 -- Alvotech (ALVO), a biotechnology company focused on developing and manufacturing biosimilar medicines, announced that the U.S. FDA has successfully closed its inspection of the company's manufacturing facility in Reykjavik, Iceland, conducted in May 2026.
The FDA classified the site as Voluntary Action Indicated (VAI), signaling that any observations identified during the inspection have been adequately addressed. Alvotech CEO Lisa Graver said the closure reflects the company's ongoing commitment to strengthening its quality systems and manufacturing operations. She added "We continue to work with the FDA to advance our recent Biologics License Applications towards approval."
The company recently resubmitted BLAs for AVT...